Provisional classification and in silico study of biopharmaceutical system based on Caco-2 cell permeability and dose number

Molecular Pharmaceutics

Volumn 10, Issue 6, 2013, Pages 2445-2461

  Pham The, Hai ^a   Garrigues, Teresa ^b   Bermejo, Marival ^c   González Álvarez, Isabel ^c   Monteagudo, Maikel Cruz ^a,d   Cabrera Pérez, Miguel Ángel ^a,b,c  

^a CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

^b UNIVERSITY OF VALENCIA   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

Biopharmaceutics Classification System (BCS); Biopharmaceutics Drug Disposition Classification System (BDDCS); Caco 2 cell permeability; dose number; Provisional Biopharmaceutical Classification (PBC); Quantitative Structure Activity Property Relationship (QSAR QSPR)

Indexed keywords

ANALYTIC METHOD; AQUEOUS SOLUTION; ARTICLE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; CELL MEMBRANE PERMEABILITY; COMPUTER MODEL; CONSENSUS; DATA BASE; DRUG PENETRATION; DRUG SOLUBILITY; MONOLAYER CULTURE; POLARIZATION; PRIORITY JOURNAL; SCREENING TEST; WORLD HEALTH ORGANIZATION;

BIOPHARMACEUTICS; CACO-2 CELLS; DRUG DISCOVERY; HUMANS; MODELS, THEORETICAL; PERMEABILITY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOLUBILITY;

EID: 84878660708     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4000585     Document Type: Article

References (68)

1. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-420
2. Chen, M. L.; Amidon, G. L.; Benet, L. Z.; Lennernas, H.; Yu, L. X. The BCS, BDDCS, and regulatory guidances Pharm. Res. 2011, 28 (7) 1774-1778
3. CDER/FDA. FDA Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Federal Drug and Food Administration: Rockville, MD, Center for Drug Evaluation and Research, 2000; www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm070246.pdf (accessed July 26, 2012).
4. CPMP/EWP/QWP/1401/98 Note for Guidance on the Investigation of Bioavailability and Bioequivalence; The European Agency for the Evaluation of Medicinal Products (EMEA): London, Evaluation of Medicines for Human Use, December 14, 2000; http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003519.pdf (accessed July 26, 2012).
5. Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms; Technical Report Series No. 937; 40th; WHO Expert Committee on Specification for Pharmaceutical Preparations, WHO Technical Report Series, No. 937, 2006; pp 391-461; http://www.who.int/medicines/publications/essentialmedicines/en/index. html (accessed March 3, 2012).
6. Cook, J. A.; Davit, B. M.; Polli, J. E. Impact of Biopharmaceutics Classification System-Based Biowaivers Mol. Pharmaceutics 2010, 7 (5) 1539-1544
7. CDER/FDA Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation; Center for Drug Evaluation and Research (CDER), November, 1995; http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070636.pdf (accessed July 26, 2012).
8. Ku, M. S. Use of the Biopharmaceutical Classification System in early drug development AAPS J. 2008, 10 (1) 208-212
9. Kasim, N. A.; Whitehouse, M.; Ramachandran, C.; Bermejo Sanz, M.; Lennernas, H.; Hussain, A. S.; Junginger, H. E.; Stavchansky, S. A.; Midha, K. K.; Shah, V. P.; Amidon, G. Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification Mol. Pharmaceutics 2004, 1 (1) 85-96
10. Dahan, A.; Miller, J. M.; Amidon, G. L. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 2009, 11 (4) 740-746
11. Takagi, T.; Ramachandran, S.; Bermejo, M.; Yamashita, S.; Yu, L. X.; Amidon, G. L. A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan Mol. Pharmaceutics 2006, 3 (6) 631-643
12. Lindenberg, M.; Kopp, S.; Dressman, J. B. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system Eur. J. Pharm. Biopharm. 2004, 58 (2) 265-278
13. Varma, M. V.; Gardner, I.; Steyn, S. J.; Nkansah, P.; Rotter, C. J.; Whitney-Pickett, C.; Zhang, H.; Di, L.; Cram, M.; Fenner, K. S.; El-Kattan, A. F. pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery Mol. Pharmaceutics 2012, 9 (5) 1199-1212
14. Nair, A. K.; Anand, O.; Chun, N.; Conner, D. P.; Mehta, M. U.; Nhu, D. T.; Polli, J. E.; Yu, L. X.; Davit, B. M. Statistics on BCS Classification of Generic Drug Products Approved Between 2000 and 2011 in the USA AAPS J. 2012, 14 (4) 664-666
15. Shawahna, R.; Rahman, N. U. Evaluation of the use of partition coefficients and molecular surface properties as predictors of drug absorption: a provisional biopharmaceutical classification of the list of national essential medicines of Pakistan DARU 2011, 19 (2) 83-99
16. The International Pharmacopoeia, 4 th ed.; World Health Organization, WHO Press: Geneva, 2006; Vols. 1 & 2, p 1520.
17. The Merck Index, 14 th ed.; Merck Research Laboratories: Whitehouse Station, NJ, 2006.
18. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 2005, 22 (1) 11-23
19. Ungell, A. L.; Artursson, P. An Overview of Caco-2 and Alternatives for Prediction of Intestinal Drug Transport and Absorption. In Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability, 2 nd ed.; van de Waterbeemd, H.; Testa, B., Eds.; Wiley-VCH: Weinheim, 2008; Vol. 40; pp 133-159.
20. Sun, H.; Pang, K. S. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study Drug Metab. Dispos. 2008, 36 (1) 102-123
21. Benet, L. Z.; Broccatelli, F.; Oprea, T. I. BDDCS Applied to Over 900 Drugs AAPS J. 2011, 13 (4) 519-547
22. WHO Model List of Essential Medicines (17th list), March 2011; http://www.who.int/medicines/publications/essentialmedicines/en/index.html (accessed July 26, 2012).
23. Electronic Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations, 32 nd ed.; Office of Generic Drugs Center for Drug Evaluation and Research, Food and Drug Administration, updated August 2012; http://www.fda.gov/downloads/Drugs/InformationOnDrugs/UCM086233.pdf (accessed July 26, 2012).
24. Kim, J. S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J.; Amidon, G. L. The Suitability of an in Situ Perfusion Model for Permeability Determinations: Utility for BCS Class I Biowaiver Requests Mol. Pharmaceutics 2006, 3 (6) 686-694
25. Pham-The, H.; Gonzalez Diaz, I.; Bermejo Sanz, M.; Mangas Sanjuan, V.; Centelles, I.; Garriges, T. M.; Cabrera Perez, M. A. In Silico Prediction of Caco-2 Permeability by a Classification QSAR Approach Mol. Inf. 2011, 30 (4) 376-385
26. Prieto, P.; Hoffmann, S.; Tirelli, V.; Tancredi, F.; González, I.; Bermejo, M.; De Angelis, I. An Exploratory Study of Two Caco-2 Cell Models for Oral Absorption: A Report on Their Within-laboratory and Between-laboratory Variability, and Their Predictive Capacity Altern. Lab. Anim. 2010, 38 (5) 367-386
27. Behrens, I.; Kissel, T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? Eur. J. Pharm. Sci. 2003, 19 (5) 433-442
28. Khandelwal, A.; Bahadduri, P. M.; Chang, C.; Polli, J. E.; Swaan, P. W.; Ekins, S. Computational models to assign biopharmaceutics drug disposition classification from molecular structure Pharm. Res. 2007, 24 (12) 2249-2262
29. Broccatelli, F.; Cruciani, G.; Benet, L. Z.; Oprea, T. I. BDDCS class prediction for new molecular entities Mol. Pharmaceutics 2012, 9 (3) 570-580
30. VolSurf+, version 1.0.4; available from Molecular Discovery Ltd., London, U.K., 2010; http://www.moldiscovery.com.
31. Marrero-Ponce, Y.; Cabrera, M. A.; Romero, V.; Bermejo, M.; Siverio, D.; Torrens, F. Prediction of Intestinal Epithelial Transport of Drug in (Caco-2) Cell Culture from Molecular Structure using in silico Approaches During Early Drug Discovery Internet Electron. J. Mol. Des. 2005, 4 (2) 124-150
32. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 1991, 175 (3) 880-885
33. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth Pharm. Res. 1997, 14 (6) 763-766
34. Volpe, D. A., Drug Permeability Studies in Regulatory Biowaiver Applications. In Drug Absorption Studies: In Situ, In Vitro and In Silico Models; Ehrhardt, C.; Kim, K.-J., Eds.; Springer: New York, 2008; Vol. VII, pp 665-680.
35. DRAGON for Windows (Software for Molecular Descriptor Calculator). 6.0; Talete srl, Milano Chemometrics and QSAR Research Group: http://www.talete.mi. it/products/dragon-description.htm.
36. Todeschini, R.; Consonni, V. Molecular Descriptors for Chemoinformatics; Wiley VCH Verlag GmbH & Co.: Weinheim, Germany, 2009; Vols. I & II.
37. Cruciani, G.; Crivori, P.; Carrupt, P. A.; Testa, B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach J. Mol. Struct.: THEOCHEM 2000, 503 (1-2) 17-30
38. STATISTICA (data analysis software system), 8.0; StatSoft, Inc.: Tulsa, OK, 2007; www.statsoft.com.
39. Fisher, R. A. The use of multiple measurements in taxonomic problems Ann. Eugenic 1936, 7, 179-188
40. Hosmer, D. W.; Lemeshow, S. Applied Logistic Regression, 2 nd ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2000; p 392.
41. SPSS (Statistical Software for the Social Sciences) 17.0; SPSS Inc.: Chicago, IL, 2008; http://www.spss.com.
42. Hanley, J. A.; McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology 1982, 143 (1) 29-36
43. Netzeva, T. I.; Worth, A.; Aldenberg, T.; Benigni, R.; Cronin, M. T.; Gramatica, P.; Jaworska, J. S.; Kahn, S.; Klopman, G.; Marchant, C. A.; Myatt, G.; Nikolova-Jeliazkova, N.; Patlewicz, G. Y.; Perkins, R.; Roberts, D.; Schultz, T.; Stanton, D. W.; van de Sandt, J. J.; Tong, W.; Veith, G.; Yang, C. Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52 Altern. Lab. Anim. 2005, 33 (2) 155-173
44. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv. Drug Delivery Rev. 2008, 60 (6) 717-733
45. Dressman, J.; Butler, J.; Hempenstall, J.; Reppas, C. The BCS: Where Do We Go from Here? Pharm. Technol. 2001, 7, 69-76
46. Tetko, I. V. Computing chemistry on the web Drug Discovery Today 2005, 10 (22) 1497-1500
47. Regardh, C. G.; Borg, K. O.; Johansson, R.; Johnsson, G.; Palmer, L. PK studies on the selective beta1-receptor antagonist metoprolol in man J. Pharmacokinet. Biopharm. 1974, 2 (4) 347-364
48. Polli, J. E.; Yu, L. X.; Cook, J. A.; Amidon, G. L.; Borchardt, R. T.; Burnside, B. A.; Burton, P. S.; Chen, M. L.; Conner, D. P.; Faustino, P. J.; Hawi, A. A.; Hussain, A. S.; Joshi, H. N.; Kwei, G.; Lee, V. H.; Lesko, L. J.; Lipper, R. A.; Loper, A. E.; Nerurkar, S. G.; Polli, J. W.; Sanvordeker, D. R.; Taneja, R.; Uppoor, R. S.; Vattikonda, C. S.; Wilding, I.; Zhang, G. Summary workshop report: Biopharmaceutics classification system - implementation challenges and extension opportunities J. Pharm. Sci. 2004, 93 (6) 1375-1381
49. Tomei, S.; Yuasa, H.; Inoue, K.; Watanabe, J. Transport functions of riboflavin carriers in the rat small intestine and colon: Site difference and effects of tricyclictype drugs Drug Delivery 2001, 8 (3) 119-124
50. Bates, T. R.; Sequeira, J. A. Use of 24-hr urinary excretion data to assess bioavailability of griseofulvin in humans J. Pharm. Sci. 1975, 64 (5) 709-710
51. Takano, R.; Sugano, K.; Higashida, A.; Hayashi, Y.; Machida, M.; Aso, Y.; Yamashita, S. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test Pharm. Res. 2006, 23 (6) 1144-1156
52. Blum, R. A.; D'Andrea, D. T.; Florentino, B. M.; Wilton, J. H.; Hilligoss, D. M.; Gardner, M. J.; Henry, E. B.; Goldstein, H.; Schentag, J. J. Increased gastric pH and the bioavailability of fluconazole and ketoconazole Ann. Intern. Med. 1991, 114 (9) 755-757
53. Elsby, R.; Surry, D. D.; Smith, V. N.; Gray, A. J. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions Xenobiotica 2008, 38 (7-8) 1140-1164
54. Yazdanian, M.; Briggs, K.; Jankovsky, C.; Hawi, A. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs Pharm. Res. 2004, 21 (2) 293-299
55. Dahan, A.; Miller, J. M.; Hilfinger, J. M.; Yamashita, S.; Yu, L. X.; Lennernas, H.; Amidon, G. L. High-Permeability Criterion for BCS Classification: Segmental/pH Dependent Permeability Considerations Mol. Pharmaceutics 2010, 7 (5) 1827-1834
56. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 1999, 16 (10) 1514-1519
57. Stenberg, P.; Norinder, U.; Luthman, K.; Artursson, P. Experimental and computational screening models for the prediction of intestinal drug absorption J. Med. Chem. 2001, 44 (12) 1927-1937
58. Hunter, J.; Jepson, M. A.; Tsuruo, T.; Simmons, N. L.; Hirst, B. H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators J. Biol. Chem. 1993, 268 (20) 14991-14997
59. Hirohashi, T.; Suzuki, H.; Chu, X. Y.; Tamai, I.; Tsuji, A.; Sugiyama, Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2) J. Pharmacol. Exp. Ther. 2000, 292 (1) 265-270
60. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 2001, 299 (2) 620-628
61. Lin, X.; Skolnik, S.; Chen, X.; Wang, J. Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model Drug Metab. Dispos. 2011, 39 (2) 265-274
62. Merino, G.; Jonker, J. W.; Wagenaar, E.; van Herwaarden, A. E.; Schinkel, A. H. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin Mol. Pharmacol. 2005, 67 (5) 1758-1764
63. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46 (1-3) 3-26
64. Chen, G.; Zheng, S.; Luo, X.; Shen, J.; Zhu, W.; Liu, H.; Gui, C.; Zhang, J.; Zheng, M.; Puah, C. M.; Chen, K.; Jiang, H. Focused combinatorial library design based on structural diversity, druglikeness and binding affinity score J. Comb. Chem. 2005, 7 (3) 398-406
65. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases J. Comb. Chem. 1999, 1 (1) 55-68
66. Zamora, I.; Oprea, T. I.; Ungell, A. L. Prediction of oral drug permeability. In Rational Approaches to Drug Design; Holtje, H. D.; Sippl, W., Eds.; Prous Science Press: Barcelona, Spain, 2001; pp 271-280.
67. Dahan, A.; Lennernäs, H.; Amidon, G. L. The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship Mol. Pharmaceutics 2012, 9 (6) 1847-1851
68. Igel, S.; Drescher, S.; Murdter, T.; Hofmann, U.; Heinkele, G.; Tegude, H.; Glaeser, H.; Brenner, S. S.; Somogyi, A. A.; Omari, T.; Schafer, C.; Eichelbaum, M.; Fromm, M. F. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux Clin. Pharmacokinet. 2007, 46 (9) 777-785